Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia

被引：0
|
作者：
Swaminathan, Mahesh
Przespolewski, Amanda
Griffiths, Elizabeth A.
Thompson, James E.
Elshoury, Amro
Walinski, Wendy
Wang, Eunice S.
机构：
[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[2] Roswell Pk Comprehens Canc Ctr, Dept Med, Leukemia Serv, Buffalo, NY USA
[3] Roswell Pk Comprehens Canc Ctr, Clin Res Serv, Buffalo, NY USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152947
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4426
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Phase I study of a single high dose of liposomal daunorubicin combined with high dose cytarabine for adult patients with relapsed/refractory acute myelogenous leukemia (AML).
    Maslak, P
    Weiss, M
    Jurcic, J
    Cathcart, K
    Heaney, M
    Berman, E
    Soignet, S
    Scheinberg, D
    Ward, S
    [J]. BLOOD, 2000, 96 (11) : 325A - 325A
  • [22] Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group study 2951
    Wells, RJ
    Adams, MT
    Alonzo, TA
    Arceci, RJ
    Buckley, J
    Buxton, AB
    Dusenbery, K
    Gamis, A
    Masterson, M
    Vik, T
    Warkentin, P
    Whitlock, JA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2940 - 2947
  • [23] Induction chemotherapy with high-dose cytarabine and mitoxantrone in elderly acute myeloid leukemia (AML) patients.
    Ramanathan, Muthalagu
    Cerny, Jan
    Raffel, Glen
    Walsh, William Vincent
    Woda, Bruce
    Miron, Patricia
    Nath, Rajneesh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
    Zeidner, Joshua F.
    Vincent, Benjamin G.
    Ivanova, Anastasia
    Moore, Dominic
    McKinnon, Karen P.
    Wilkinson, Alec D.
    Mukhopadhyay, Rupkatha
    Mazziotta, Francesco
    Knaus, Hanna A.
    Foster, Matthew C.
    Coombs, Catherine C.
    Jamieson, Katarzyna
    Van Deventer, Hendrik
    Webster, Jonathan A.
    Prince, Gabrielle T.
    DeZern, Amy E.
    Smith, B. Douglas
    Levis, Mark J.
    Montgomery, Nathan D.
    Luznik, Leo
    Serody, Jonathan S.
    Gojo, Ivana
    [J]. BLOOD CANCER DISCOVERY, 2021, 2 (06): : 616 - 629
  • [25] Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma
    van der Spek, Ellen
    Bloem, Andries C.
    van de Donk, Niels W. C. J.
    Bogers, Lijnie H.
    van der Griend, Rene
    Kramer, Mark H.
    de Weerdt, Okke
    Wittebol, Shulamiet
    Lokhorst, Henk M.
    [J]. HAEMATOLOGICA, 2006, 91 (04) : 542 - 545
  • [26] A Phase 1b (OX1222) Dose-Finding Study of OXi4503 Combined with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
    Watts, Justin M.
    Swords, Ronan T.
    Cogle, Christopher R.
    Lin, Tara L.
    [J]. BLOOD, 2016, 128 (22)
  • [27] Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute Myeloid Leukemia?
    Bertoli, Sarah
    Gadaud, Noemie
    Tavitian, Suzanne
    Sarry, Audrey
    Berard, Emilie
    Huguet, Francoise
    Recher, Christian
    [J]. BLOOD, 2016, 128 (22)
  • [28] Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study
    van Eijkelenburg, Natasha K. A.
    Rasche, Mareike
    Ghazaly, Essam
    Dworzak, Michael N.
    Klingebiel, Thomas
    Rossig, Claudia
    Leverger, Guy
    Stary, Jan
    De Bont, Eveline S. J. M.
    Chitu, Dana A.
    Bertrand, Yves
    Brethon, Benoit
    Strahm, Brigitte
    van der Sluis, Inge M.
    Kaspers, Gertjan J. L.
    Reinhardt, Dirk
    Zwaan, C. Michel
    [J]. HAEMATOLOGICA, 2018, 103 (09) : 1484 - 1492
  • [29] A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia
    Bassan, R
    Lerede, T
    Buelli, M
    Borleri, G
    Bellavita, P
    Rambaldi, A
    Barbul, T
    [J]. HAEMATOLOGICA, 1998, 83 (05) : 422 - 427
  • [30] Determination of the Maximum Tolerated Dose of Panobinostat in Combination with Cytarabine and Mitoxantrone As Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia
    Schlenk, Richard F.
    Krauter, Juergen
    Schaich, Markus
    Bouscary, Didier
    Dombret, Herve
    Winiger, Ivo J.
    Squier, Margaret
    Zahlten, Anita
    Wang, Lu
    Ottmann, Oliver G.
    [J]. BLOOD, 2011, 118 (21) : 195 - 195
12345